HCV drug combo linked to side effects after liver transplant

05/16/2013 | Aidsmap

Treating hepatitis C-positive patients who underwent a liver transplant with a combination of three drugs -- pegylated interferon, ribavirin and telaprevir -- increased sustained viral response rates even for difficult cases, but adverse events were also common, according to findings presented at a liver meeting. Among the adverse events were the need for transfusions to address blood cell deficiencies. The study evaluated data from six U.S. centers.

View Full Article in:

Aidsmap

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA